AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...
In practice it is logical that inhalers are prescribed only after patients have received training and demonstrated their ability to use the device. However, many patients are unable to use their ...
Understanding the components of a reference marketed pMDI is needed to develop a generic pMDI. Developing a generic equivalent to a current, marketed pressurized metered dose inhaler (pMDI) product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results